GlassScriptPhysician profile
Mushtaque Ahmed
NPI 1689843518
$9,136.34
in general payments reported to CMS, 2019-2025
29 companies · $256 in 2025
The $256 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $7,400 · 2022: $435 · 2023: $642 · 2024: $403 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,301.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $7,465.84 | 2021-2025 | Onyx Frontier, Inceptiv |
| Novo Nordisk INC | $207.27 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $173.86 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $160.94 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Boston Scientific Corporation | $158.69 | 2023-2024 | Watchman Flx |
| Ancora Heart, INC. | $134.47 | 2022 | |
| Idorsia Pharmaceuticals US INC | $107.92 | 2022-2023 | Quviviq |
| Pfizer INC. | $100.61 | 2024-2025 | |
| Bard Peripheral Vascular, INC. | $93.08 | 2022 | |
| Mylan Specialty L.P. | $57.59 | 2022 | |
| Sanofi-Aventis U.S. LLC | $53.51 | 2022-2023 | |
| Glaxosmithkline, LLC. | $50.14 | 2022-2023 | Shingrix |
| Astrazeneca Pharmaceuticals LP | $39.12 | 2022-2024 | Breztri |
| Amgen INC. | $32.79 | 2023-2024 | Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $29.08 | 2023 | Nuedexta |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $27.54 | 2025 | Omnipod |
| Axsome Therapeutics, INC. | $26.57 | 2023 | Sunosi |
| Corcept Therapeutics | $22.48 | 2025 | Korlym |
| Biohaven Pharmaceutical Holding Company LTD. | $21.68 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.74 | 2023 | Xifaxan, Trulance |
| Abbvie INC. | $19.44 | 2023 | Ubrelvy |
| Astellas Pharma US INC | $18.76 | 2024 | Veozah |
| Abbott Laboratories | $18.74 | 2024 | Proclaim |
| Merck Sharp & Dohme LLC | $17.68 | 2023 | Steglatro, Belsomra |
| Tolmar, INC. | $17.23 | 2023 | |
| Phathom Pharmaceuticals, INC. | $16.67 | 2024 | Voquezna |
| Philips North America LLC | $16.54 | 2024 | (Ck4) Mcot |
| Paratek Pharmaceuticals, INC. | $13.94 | 2024 | Nuzyra |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $13.42 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mushtaque Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.